| Organic synthesis provides opportunities to transform drug discovery DC Blakemore, L Castro, I Churcher, DC Rees, AW Thomas, DM Wilson, ... Nature chemistry 10 (4), 383-394, 2018 | 1294 | 2018 |
| The role of ligand efficiency metrics in drug discovery AL Hopkins, GM Keserü, PD Leeson, DC Rees, CH Reynolds Nature reviews Drug discovery 13 (2), 105-121, 2014 | 1183 | 2014 |
| Fragment-based lead discovery DC Rees, M Congreve, CW Murray, R Carr Nature Reviews Drug Discovery 3 (8), 660-672, 2004 | 1055 | 2004 |
| The rise of fragment-based drug discovery CW Murray, DC Rees Nature chemistry 1 (3), 187-192, 2009 | 957 | 2009 |
| Solid-phase organic reactions: a review of the recent literature PHH Hermkens, HCJ Ottenheijm, D Rees Tetrahedron 52 (13), 4527-4554, 1996 | 750 | 1996 |
| A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin‐based synthetic host A Bom, M Bradley, K Cameron, JK Clark, J Van Egmond, H Feilden, ... Angewandte Chemie International Edition 41 (2), 265-270, 2002 | 680 | 2002 |
| Solid-phase organic reactions II: A review of the literature Nov 95–Nov 96 PHH Hermkens, HCJ Ottenheijm, DC Rees Tetrahedron 53 (16), 5643-5678, 1997 | 600 | 1997 |
| Fragment-based lead discovery: leads by design RAE Carr, M Congreve, CW Murray, DC Rees Drug discovery today 10 (14), 987-992, 2005 | 499 | 2005 |
| Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity S Howard, V Berdini, JA Boulstridge, MG Carr, DM Cross, J Curry, ... Journal of medicinal chemistry 52 (2), 379-388, 2009 | 399 | 2009 |
| The'rule of three'for fragment-based drug discovery: where are we now? H Jhoti, G Williams, DC Rees, CW Murray Nature Reviews Drug Discovery 12 (8), 644-644, 2013 | 358 | 2013 |
| Discovery and pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor TPS Perera, E Jovcheva, L Mevellec, J Vialard, D De Lange, T Verhulst, ... Molecular cancer therapeutics 16 (6), 1010-1020, 2017 | 334 | 2017 |
| Cyclodextrin-Derived Host Molecules as Reversal Agents for the Neuromuscular Blocker Rocuronium Bromide: Synthesis and Structure− Activity Relationships JM Adam, DJ Bennett, A Bom, JK Clark, H Feilden, EJ Hutchinson, ... Journal of Medicinal Chemistry 45 (9), 1806-1816, 2002 | 332 | 2002 |
| Discovery of (2, 4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1, 3-dihydroisoindol-2-yl] methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone … AJ Woodhead, H Angove, MG Carr, G Chessari, M Congreve, JE Coyle, ... Journal of medicinal chemistry 53 (16), 5956-5969, 2010 | 316 | 2010 |
| Solid-phase organic reactions III: A review of the literature Nov 96–Dec 97 S Booth, PHH Hermkens, HCJ Ottenheijm, DC Rees Tetrahedron 54 (51), 15385-15443, 1998 | 315 | 1998 |
| Experiences in fragment-based drug discovery CW Murray, ML Verdonk, DC Rees Trends in pharmacological sciences 33 (5), 224-232, 2012 | 306 | 2012 |
| Opportunity Knocks: Organic Chemistry for Fragment-Based Drug Discovery (FBDD). CW Murray, DC Rees Angewandte Chemie International Edition 55 (2), 2016 | 202 | 2016 |
| CI‐977, a novel and selective agonist for the κ‐opioid receptor JC Hunter, GE Leighton, KG Meecham, SJ Boyle, DC Horwell, DC Rees, ... British journal of pharmacology 101 (1), 183-189, 1990 | 196 | 1990 |
| Synthesis of tertiary amines using a polystyrene (REM) resin AR Brown, DC Rees, Z Rankovic, JR Morphy Journal of the American Chemical Society 119 (14), 3288-3295, 1997 | 159 | 1997 |
| A novel linker strategy for solid-phase synthesis JR Morphy, Z Rankovic, DC Rees Tetrahedron letters 37 (18), 3209-3212, 1996 | 142 | 1996 |
| Validity of ligand efficiency metrics CW Murray, DA Erlanson, AL Hopkins, GM Keserü, PD Leeson, ... ACS medicinal chemistry letters 5 (6), 616-618, 2014 | 141 | 2014 |
Miles CongreveIsomorphic LabsDirección de correo verificada de isomorphiclabs.com